An Open Label, Prospective, Observational, Local, Non-interventional Study of BeVacizumab (Avastin) and IntErpherone (IFN) Alpha 2a in Patients With Metastatic and Locally Advanced Renal Cell CAncer (VERA Study).
Phase of Trial: Phase IV
Latest Information Update: 12 Jul 2016
At a glance
- Drugs Bevacizumab (Primary) ; Interferon alpha-2a (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Acronyms VERA
- Sponsors Roche
- 31 Jul 2015 Status changed from active, no longer recruiting to completed as reported in ClinicalTrial.gov.
- 19 Nov 2014 Planned End Date changed from 1 Oct 2014 to 1 Jun 2015 as reported in ClinicalTrial.gov.
- 19 Nov 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Jun 2015 as reported in ClinicalTrial.gov.